Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.51 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430566 | 0.80 | CHRNA7 (0.57) | LMNA | |
| SCHEMBL3433510 | 0.80 | HRH4 (0.52) | CHRNB2CHRNA4MAP3K12HRH4 | |
| SCHEMBL3432395 | 0.78 | MAP3K12 (0.52) | MAP3K12LMNA | |
| SCHEMBL3430563 | 0.77 | HRH4 (0.54) | CHRNB2CHRNA4CSNK1EHRH4 | |
| SCHEMBL15393065 | 0.77 | HRH4 (0.48) | CHRNB2CHRNA4MAP3K12CSNK1EHRH4 | |
| SCHEMBL3431236 | 0.75 | LMNA (0.42) | LMNA | |
| SCHEMBL4254231 | 0.73 | DHFR (0.46) | LMNA | |
| SCHEMBL3431233 | 0.72 | HRH4 (0.52) | CHRNB2CHRNA4CSNK1EHRH4 | |
| SCHEMBL3433540 | 0.72 | HRH4 (0.44) | CHRNB2CHRNA4CSNK1EHRH4CHRNB4 | |
| SCHEMBL5786902 | 0.71 | ALDH1A1 (0.54) | CHRNB2CHRNA4LMNACSNK1EHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017007658-A1 | A COMBINATION FOR IMMUNE MEDIATED CANCER TREATMENT | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-12 | — | — | WO | claimed |
| EP-2265607-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | Rigel Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009103032-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |